Pre-surgery hormone therapy with or without PI3K inhibitor
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new, untreated breast tumor on one side that was confirmed by core biopsy (not fine-needle aspiration).
- Your tumor can be measured on scans, and it is in a certain early stage (cT1b to cT3) regardless of lymph node status.
- Your tumor is ER-positive and HER2-positive, and it has a PIK3CA mutation confirmed by a central lab; testing also checks PR, Ki-67, and tumor-infiltrating lymphocytes.
- You must be able to have heart tests (ECG and heart ultrasound) showing good heart pumping (LVEF above 55%) within 3 months.
- Your blood counts and liver function must meet lab limits, and your HbA1c must be under 6.5% (blood sugar control).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
This trial tests a combination of medications (inavolisib, pertuzumab, trastuzumab, and nab-paclitaxel) given before surgery to shrink tumors in people with HER2-positive early breast cancer that also has a specific gene change (PIK3CA mutation). The goal is to see if this treatment is effective and safe.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This study tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) for women with advanced breast cancer that is hormone-receptor positive and HER2-negative, with a specific genetic mutation (PIK3CA). The goal is to see if this combination can shrink or control the cancer better than standard treatments.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.